We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+9.41%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$1.08B
(+126%)
Cap. Flow
+$347M
Cap. Flow
% of AUM
17.97%
Top 10 Holdings %
Top 10 Hldgs %
58.78%
Holding
104
New
42
Increased
25
Reduced
17
Closed
19
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARK Genomic Revolution ETF
ARKG
|
+$80M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$31.3M |
| 3 |
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
|
+$24.2M |
| 4 |
Community Health Systems
CYH
|
+$23.5M |
| 5 |
McKesson
MCK
|
+$22.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$23.6M |
| 2 |
The Ensign Group
ENSG
|
+$15.4M |
| 3 |
CATALENT, INC.
CTLT
|
+$13M |
| 4 |
HSKA
Heska Corp
HSKA
|
+$11.5M |
| 5 |
RAD
Rite Aid Corporation
RAD
|
+$10.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.91% |
| 2 | Miscellaneous | 40.99% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RAD
76
DELISTED
Rite Aid Corporation
RAD
| $1.11M | 0.06% |
54,025
-477,979
| -90% | -$10.4M |
2020 Q4
1 quarter
|
|
77
InflaRx
IFRX
$212M
| $1.05M | 0.05% |
+268,634
| New | +$1.38M |
2021 Q1
0 quarters
|
|
78
Cabaletta Bio
CABA
$263M
| $853K | 0.04% |
+76,849
| New | +$939K |
2021 Q1
0 quarters
|
|
79
DELISTED
GoHealth
GOCO
| $805K | 0.04% |
4,593
+2,614
| +132% | +$527K |
2020 Q3
2 quarters
|
|
|
IMMP
80
Immutep
IMMP
$23.7M
| $767K | 0.04% |
+12,495
| New | +$761K |
2021 Q1
0 quarters
|
|
81
CALL
Acadia Pharmaceuticals
ACAD
$3.4B
| $645K | 0.03% |
+25,000
| New | +$1.1M |
2021 Q1
0 quarters
|
|
82
DELISTED
Apellis Pharmaceuticals
APLS
| $554K | 0.03% |
12,900
+9,084
| +238% | +$430K |
2018 Q2
11 quarters
|
|
83
QuidelOrtho
QDEL
$954M
| $529K | 0.03% |
4,132
-36,451
| -90% | -$6.73M |
2020 Q3
2 quarters
|
|
|
APTO
84
DELISTED
Aptose Biosciences, Inc.
APTO
| $478K | 0.02% |
+178
| New | +$353K |
2021 Q1
0 quarters
|
|
85
Repligen
RGEN
$11.7B
| $278K | 0.01% |
+1,428
| New | +$293K |
2021 Q1
0 quarters
|
|
86
Altimmune
ALT
$459M
| – | – |
-380,000
| Closed | -$4.29M | – |
|
87
AnaptysBio
ANAB
$1.46B
| – | – |
-88,334
| Closed | -$1.9M | – |
|
88
DELISTED
Astria Therapeutics
ATXS
| – | – |
-87,007
| Closed | -$1.12M | – |
|
89
Aurinia Pharmaceuticals
AUPH
$2.23B
| – | – |
-604,368
| Closed | -$8.36M | – |
|
90
Autolus Therapeutics
AUTL
$458M
| – | – |
-154,981
| Closed | -$1.39M | – |
|
91
BioCryst Pharmaceuticals
BCRX
$2.05B
| – | – |
-491,852
| Closed | -$3.66M | – |
|
92
DELISTED
Carisma Therapeutics
CARM
| – | – |
-77,991
| Closed | -$2.11M | – |
|
93
CALL
Cytokinetics
CYTK
$8.89B
| – | – |
-10,000
| Closed | -$208K | – |
|
94
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-18,925
| Closed | -$359K | – |
|
95
DELISTED
Merus
MRUS
| – | – |
-14,445
| Closed | -$253K | – |
|
96
Sanofi
SNY
$96.5B
| – | – |
-68,138
| Closed | -$3.31M | – |
|
|
97
Sarepta Therapeutics
SRPT
$1.88B
| – | – |
-138,644
| Closed | -$23.6M | – |
|
98
Protara Therapeutics
TARA
$147M
| – | – |
-36,310
| Closed | -$879K | – |
|
99
Zymeworks
ZYME
$1.85B
| – | – |
-5,405
| Closed | -$255K | – |
|
100
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| – | – |
-17,205
| Closed | -$1.69M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Eversept Partners held 104 positions worth $1.93B, up 126% from $852M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Eversept Partners deployed $347M of net new capital in Q1 2021, opening 42 new positions and adding to 25 existing holdings. Its largest new stake was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was The Ensign Group, an estimated $15.4M trimmed.
- Eversept Partners's largest Q1 2021 buy was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
- Eversept Partners added most to Community Health Systems in Q1 2021, an estimated $23.5M increase.
- Eversept Partners's biggest Q1 2021 reduction was The Ensign Group, cutting an estimated $15.4M.
- Eversept Partners fully exited Sarepta Therapeutics in Q1 2021, selling an estimated $23.6M.
- Eversept Partners's ten largest holdings make up 59% of its $1.93B portfolio in Q1 2021.
- Eversept Partners opened 42 new positions and closed 19 in Q1 2021.
- Eversept Partners's portfolio value rose 126% quarter-over-quarter to $1.93B.
Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.